BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steiner MA, Sciarretta C, Pasquali A, Jenck F. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol 2013;4:165. [PMID: 24416020 DOI: 10.3389/fphar.2013.00165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kakizaki M, Tsuneoka Y, Takase K, Kim SJ, Choi J, Ikkyu A, Abe M, Sakimura K, Yanagisawa M, Funato H. Differential Roles of Each Orexin Receptor Signaling in Obesity. iScience 2019;20:1-13. [PMID: 31546102 DOI: 10.1016/j.isci.2019.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Lee JM, Kim U, Yang H, Ryu B, Kim J, Sakuma T, Yamamoto T, Park JH. TALEN-mediated generation of Nkx3.1 knockout rat model. Prostate 2021;81:182-93. [PMID: 33368416 DOI: 10.1002/pros.24095] [Reference Citation Analysis]
4 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
5 Steiner MA, Winrow CJ. Opportunities and perspectives for developing orexin receptor antagonists. Front Neurosci 2014;8:158. [PMID: 24971050 DOI: 10.3389/fnins.2014.00158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Blanke K, Schlegel F, Raasch W, Bader M, Dähnert I, Dhein S, Salameh A. Effect of Angiotensin(1-7) on Heart Function in an Experimental Rat Model of Obesity. Front Physiol 2015;6:392. [PMID: 26733884 DOI: 10.3389/fphys.2015.00392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Mariné-casadó R, Domenech-coca C, del Bas JM, Bladé C, Caimari A, Arola L. Cherry consumption out of season alters lipid and glucose homeostasis in normoweight and cafeteria-fed obese Fischer 344 rats. The Journal of Nutritional Biochemistry 2019;63:72-86. [DOI: 10.1016/j.jnutbio.2018.09.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Blanco-Ania D, Heus R, Rutjes FPJT. Privileged heterocycles: bioactivity and synthesis of 1,9-diazaspiro[5.5]undecane-containing compounds. Chem Heterocycl Compd (N Y) 2017;53:827-45. [PMID: 32214420 DOI: 10.1007/s10593-017-2133-6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Tsuneki H, Sasaoka T, Sakurai T. Sleep Control, GPCRs, and Glucose Metabolism. Trends Endocrinol Metab 2016;27:633-42. [PMID: 27461005 DOI: 10.1016/j.tem.2016.06.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
10 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
11 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
12 Yu D, Zhong Y, Li X, Li Y, Li X, Cao J, Fan Z, Fan H, Yuan L, Xu B, Yuan Y, Zhang H, Ji Z, Wen JG, Zhang M, Nesland JM, Suo Z. Generation of TALEN-mediated FH knockout rat model. Oncotarget 2016;7:61656-69. [PMID: 27556703 DOI: 10.18632/oncotarget.11429] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
13 Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2016;26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Barson JR, Leibowitz SF. Orexin/Hypocretin System: Role in Food and Drug Overconsumption. Int Rev Neurobiol 2017;136:199-237. [PMID: 29056152 DOI: 10.1016/bs.irn.2017.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
15 Nohara K, Yoo SH, Chen ZJ. Manipulating the circadian and sleep cycles to protect against metabolic disease. Front Endocrinol (Lausanne) 2015;6:35. [PMID: 25852644 DOI: 10.3389/fendo.2015.00035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
16 Muthmainah M, Gogos A, Sumithran P, Brown RM. Orexins (hypocretins): The intersection between homeostatic and hedonic feeding. J Neurochem 2021;157:1473-94. [PMID: 33608877 DOI: 10.1111/jnc.15328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Franco-Tormo MJ, Salas-Crisostomo M, Rocha NB, Budde H, Machado S, Murillo-Rodríguez E. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity. J Mol Neurosci 2018;65:10-6. [PMID: 29732484 DOI: 10.1007/s12031-018-1076-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Bojanowska E, Ciosek J. Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior. Curr Neuropharmacol 2016;14:118-42. [PMID: 26549651 DOI: 10.2174/1570159x14666151109103147] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
19 Beig MI, Horiuchi J, Dampney RA, Carrive P. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus. Clin Exp Pharmacol Physiol 2015;42:1059-67. [DOI: 10.1111/1440-1681.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]